Loading clinical trials...
Loading clinical trials...
A Phase III, Open Label, Multicenter, Single Arm Study to Assess the Safety, Tolerability and Immunogenicity of VLA2001 in Volunteers Aged ≥ 56 Years.
Conditions
Interventions
VLA2001
Locations
8
New Zealand
Southern Clinical Trials Waitemata
Auckland, Birkenhead, New Zealand
Lakeland Clinical Trials Waikato
Hamilton, Nawton, New Zealand
Southern Clinical Trials Totara
Auckland, New Lynn, New Zealand
Lakeland Clinical Trials Culloden
Papamoa, Papamoa Beach, New Zealand
Southern Clinical Trials Remuera
Auckland, Remuera, New Zealand
Southern Clinical Trials Tasman
Nelson, Stoke, New Zealand
Start Date
August 9, 2021
Primary Completion Date
November 10, 2021
Completion Date
November 18, 2022
Last Updated
September 1, 2023
Lead Sponsor
Valneva Austria GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions